DK3173102T3 - FGFR-FC-fusionsprotein og anvendelse deraf - Google Patents

FGFR-FC-fusionsprotein og anvendelse deraf Download PDF

Info

Publication number
DK3173102T3
DK3173102T3 DK16205128.8T DK16205128T DK3173102T3 DK 3173102 T3 DK3173102 T3 DK 3173102T3 DK 16205128 T DK16205128 T DK 16205128T DK 3173102 T3 DK3173102 T3 DK 3173102T3
Authority
DK
Denmark
Prior art keywords
fgfr
fusion protein
fusion
protein
Prior art date
Application number
DK16205128.8T
Other languages
Danish (da)
English (en)
Inventor
Jianmin Fang
Dong Li
Original Assignee
Remegen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remegen Ltd filed Critical Remegen Ltd
Application granted granted Critical
Publication of DK3173102T3 publication Critical patent/DK3173102T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK16205128.8T 2011-05-20 2012-05-18 FGFR-FC-fusionsprotein og anvendelse deraf DK3173102T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110132218A CN102219860B (zh) 2011-05-20 2011-05-20 FGFR-Fc融合蛋白及其用途
EP12788998.8A EP2711376B1 (en) 2011-05-20 2012-05-18 Fgfr-fc fusion protein and use thereof

Publications (1)

Publication Number Publication Date
DK3173102T3 true DK3173102T3 (da) 2020-02-24

Family

ID=44776585

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16205128.8T DK3173102T3 (da) 2011-05-20 2012-05-18 FGFR-FC-fusionsprotein og anvendelse deraf

Country Status (11)

Country Link
US (2) US9273137B2 (enExample)
EP (2) EP3173102B1 (enExample)
JP (1) JP2014513941A (enExample)
KR (2) KR101660336B1 (enExample)
CN (1) CN102219860B (enExample)
AU (1) AU2012261412B2 (enExample)
BR (1) BR112013022285B1 (enExample)
CA (1) CA2834584C (enExample)
DK (1) DK3173102T3 (enExample)
RU (1) RU2560573C2 (enExample)
WO (1) WO2012159550A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CA2880013C (en) * 2012-07-24 2022-11-29 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US20150344855A1 (en) * 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
WO2014190147A2 (en) * 2013-05-23 2014-11-27 Five Prime Therapeutics, Inc. Methods of treating cancer
DK3102577T3 (en) * 2014-02-07 2018-11-12 Principia Biopharma Inc QUINOLONDERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
CN105983093A (zh) * 2015-02-11 2016-10-05 烟台荣昌生物工程有限公司 血管新生因子融合蛋白在制备用于治疗与血管新生相关的眼部疾病药物中的应用
KR102432192B1 (ko) 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
SG11201908528UA (en) * 2017-03-17 2019-10-30 Vaximm Ag Novel pd-l1 targeting dna vaccine for cancer immunotherapy
BR112021003275A2 (pt) 2018-12-07 2021-06-22 Remegen Co., Ltd. inibidor de angiogênese bifuncional e uso do mesmo
CN116143941B (zh) * 2022-09-08 2024-06-04 浙江省血液中心 一种KIR3DL1-IgG-Fc融合重组蛋白、应用及试剂盒
CN116199744B (zh) * 2023-03-23 2024-06-25 湖南中晟全肽生物科技股份有限公司 一种结合fgfr2受体的多肽及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
DE102005007665A1 (de) 2005-02-19 2006-08-31 Degussa Ag Folie auf Basis eines Polyamidblends
NZ565511A (en) * 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
AU2007257683A1 (en) 2006-06-12 2007-12-21 Symphogen A/S Pan-cell surface receptor- specific therapeutics
RU2341198C2 (ru) * 2006-11-27 2008-12-20 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ оценки ангиогенных факторов при химиотерапии рака молочной железы
PE20081250A1 (es) * 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
ZA200903134B (en) * 2006-11-28 2010-08-25 Centelion Modified soluble FGF receptor FC fusions with improved biological activity
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
CN102171343B (zh) * 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
PT2498799T (pt) * 2009-11-13 2016-11-04 Five Prime Therapeutics Inc Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途

Also Published As

Publication number Publication date
RU2560573C2 (ru) 2015-08-20
EP2711376A4 (en) 2015-06-03
AU2012261412B2 (en) 2016-02-25
BR112013022285A2 (pt) 2016-12-06
US20130195864A1 (en) 2013-08-01
WO2012159550A1 (zh) 2012-11-29
KR101660336B1 (ko) 2016-09-27
US20160176945A1 (en) 2016-06-23
AU2012261412A1 (en) 2013-08-29
RU2013140184A (ru) 2015-07-10
EP3173102A1 (en) 2017-05-31
EP2711376A1 (en) 2014-03-26
CN102219860B (zh) 2012-09-12
EP2711376B1 (en) 2018-07-25
CN102219860A (zh) 2011-10-19
KR20130119978A (ko) 2013-11-01
KR20160011241A (ko) 2016-01-29
US9273137B2 (en) 2016-03-01
BR112013022285B1 (pt) 2020-05-12
CA2834584C (en) 2019-05-14
CA2834584A1 (en) 2012-11-29
JP2014513941A (ja) 2014-06-19
EP3173102B1 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
IL288203A (en) Meditopes and meditope-binding antibodies and uses thereof
DK3321287T3 (da) Fusionsproteiner og kombinationsvacciner
HRP20150241T1 (xx) Antikancerogeni fuzijski protein
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2794654T3 (da) Anti-phf-tau-antistoffer og deres anvendelser
CO7020851A2 (es) Proteínas y péptidos modificados
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
HUE046156T2 (hu) Szerpin fúziós polipeptidek és alkalmazásuk módszerei
HUE054437T2 (hu) Anti-CGRP készítmények és alkalmazásuk
DK3381943T3 (da) Anti-kit-antistoffer og anvendelser deraf
DK2668210T3 (da) Anti-kit antistoffer og anvendelser deraf
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
DK3597644T3 (da) Kationiske aminlipider og anvendelser deraf
DK3333188T3 (da) Anti-NGF-antistoffer og deres anvendelse
DK2920197T3 (da) Prolinlåste sammenhæftede peptider og anvendelser deraf
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
BR112015003838A2 (pt) formulações de anticorpo e proteína
IL232247A0 (en) Polypeptide constructs and uses thereof
ME03075B (me) Prolaktin receptor vezujući proteini i njihova upotreba
IL231777A0 (en) Antibodies against tl1a and uses thereof
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
DK2785375T3 (da) Anti-pd-l1-antistoffer og anvendelser deraf
DK2812443T3 (da) Cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2552434T3 (da) Peptider og anvendelse deraf
DK3197164T3 (da) Afkodningsanordning og afkodningsfremgangsmåde